prikaz prve stranice dokumenta Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem
  Download
PDF 601.53 KB
Scientific paper - Original scientific paper
Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem
Biomedicines, 10 (2022), 11; 2892. https://doi.org/10.3390/biomedicines10112892
Sertić, Zrinka; Lucijanić, Marko; Bašić-Kinda, Sandra; Serventi Seiwerth, Ranka; Periša, Vlatka; Sertić, Dubravka; Coha, Božena; Pulanić, Dražen; Perić, Zinaida; Desnica, Lana; Mikulić, Mirta; Vodanović, Marijo; Radman-Livaja, Ivo; Šegulja, Dragana; Rogić, Dunja; Valković, Toni; Aurer, Igor; Duraković, Nadira More authors...

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Sertić, Z., Lucijanić, M., Bašić Kinda, S., Serventi Seiwerth, R., Periša, V., Sertić, D. ... Duraković, N. (2022). Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem. Biomedicines, 10. (11). doi: 10.3390/biomedicines10112892

Sertić, Zrinka, et al. "Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem." Biomedicines, vol. 10, no. 11, 2022. https://doi.org/10.3390/biomedicines10112892

Sertić, Zrinka, Marko Lucijanić, Sandra Bašić Kinda, Ranka Serventi Seiwerth, Vlatka Periša, Dubravka Sertić, Božena Coha, et al. "Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem." Biomedicines 10, no. 11 (2022). https://doi.org/10.3390/biomedicines10112892

Sertić, Z., et al. (2022) 'Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem', Biomedicines, 10(11). doi: 10.3390/biomedicines10112892

Sertić Z, Lucijanić M, Bašić Kinda S, Serventi Seiwerth R, Periša V, Sertić D, and sur.. Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem. Biomedicines [Internet]. 2022 November 11 [cited 2024 December 24];10(11). doi: 10.3390/biomedicines10112892

Z. Sertić, et al., "Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem", Biomedicines, vol. 10, no. 11, November 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:409104. [Accessed: 24 December 2024]

Metadata
Title (english)Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem
AuthorZrinka Sertić
AuthorMarko Lucijanić
AuthorSandra Bašić-Kinda
AuthorRanka Serventi Seiwerth
AuthorVlatka Periša
AuthorDubravka Sertić
AuthorBožena Coha
AuthorDražen Pulanić
AuthorZinaida Perić
AuthorLana Desnica
AuthorMirta Mikulić
AuthorMarijo Vodanović
AuthorIvo Radman-Livaja
AuthorDragana Šegulja
AuthorDunja Rogić
AuthorToni Valković
AuthorIgor Aurer
AuthorNadira Duraković
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Disease- and treatment-mediated immunodeficiency might render SARS-CoV-2 vaccines less effective in patients with hematologic diseases. We performed a prospective non-interventional study to evaluate humoral response after one and two doses of mRNA-1273, BNT162b2, or ChAdOx1 nCoV-19 vaccine in 118 patients with different malignant or non-malignant hematologic diseases from three Croatian treatment centers. An electrochemiluminescent assay was used to measure total anti-SARS-CoV-2 S-RBD antibody titers. After one vaccine dose, 20/66 (33%) achieved seropositivity with a median antibody titer of 6.1 U/mL. The response rate (58/90, 64.4%) and median antibody titer (>250 U/mL) were higher after two doses. Seropositivity varied with diagnosis (overall p < 0.001), with the lowest rates in lymphoma (34.6%) and chronic lymphocytic leukemia (52.5%). The overall response rate in chronic myeloproliferative neoplasms (CMPN) was 81.3% but reached 100% in chronic myeloid leukemia and other non-myelofibrosis CMPN. At univariable analysis, age > 67 years, non-Hodgkin’s lymphoma, active treatment, and anti-CD20 monoclonal antibody therapy increased the likelihood of no vaccine response, while hematopoietic stem cell recipients were more likely to respond. Age and anti-CD20 monoclonal antibody therapy remained associated with no response in a multivariable model. Patients with the hematologic disease have attenuated responses to SARS-CoV-2 vaccines, and significant variations in different disease subgroups warrant an individualized approach.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleBiomedicines
Numberingvol. 10, no. 11, 2892
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines10112892
URN:NBNurn:nbn:hr:184:409104
Publication2022-11-11
Document URLhttps://www.mdpi.com/2227-9059/10/11/2892
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-01-26 21:21:56